Circadian rest-activity rhythm disorders in advanced cancer: assessment, diagnosis and clinical correlates Authors: Craig Gouldthorpe, Andrew Neil Davies Published: 2025 ABSTRACT AbstractIntroduction and aimsCircadian rest-activity rhythms describe patterns in rest and physical activity across and between 24-hour periods. Research highlights important associations between circadian disruption, including the rest-activity rhythm, and clinical outcomes in patients with cancer. This study aimed to assess the circadian rest-activity rhythms, and prevalence of circadian rest-activity rhythm disorders (CARDs), in patients with advanced cancer.MethodsAn observational study of 72 outpatients with locally advanced or metastatic cancer took place over a 1-year period, considering objective (accelerometry) and subjective (patient diary) measures of circadian rest-activity rhythms, patient-reported outcomes (Memorial Symptom Assessment Scale-Short Form, European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire, brief Pittsburgh Sleep Quality Index and Epworth Sleepiness Scale) and clinical markers.ResultsCARDs affected up to 60% of patients with advanced cancer. Increased circadian disruption was seen in patients with more advanced disease, particularly with metastatic organ involvement (p=0.038), poorer performance status (p=0.018), higher inflammatory status (p=0.018), anaemia (p=0.007) and iron deficiency (p=0.002). The study also highlights that patients with advanced cancer and a CARD diagnosis have a higher symptom burden, particularly fatigue (p=0.003) and drowsiness (p=0.005), higher symptom-related distress (p<0.001), a poorer Global Health tatus (p=0.005) and poorer functioning subscales (p<0.014).ConclusionThis is the first study to assess circadian rest-activity rhythms in accordance with new assessment and diagnostic guidelines. Further research is now required to validate the diagnostic criteria, standardise technical approaches to assessment and consider risk factors for the development of a CARD and additional clinical outcomes of interest.Keywords: Cancer, Clinical assessment, Palliative Care, Quality of life, Symptoms and symptom management, Supportive care WHAT IS ALREADY KNOWN ON THIS TOPIC Circadian rhythms are commonly disordered in patients with advanced cancer. Disordered circadian rhythms may impact clinical outcomes, including worse symptomatology, quality of life and survival. Approaches to investigating and reporting circadian rhythms have previously lacked standardisation. However, recent guidelines outline an approach to the assessment of an observable circadian rest-activity rhythm and the diagnosis of circadian rest-activity rhythm disorders (CARDs) in patients with cancer. This study assessed the circadian rest-activity rhythms, prevalence of CARDs and associations with patient characteristics and clinical outcomes in a cohort of patients with advanced cancer. Circadian rhythms are commonly disordered in patients with advanced cancer. Disordered circadian rhythms may impact clinical outcomes, including worse symptomatology, quality of life and survival. Approaches to investigating and reporting circadian rhythms have previously lacked standardisation. However, recent guidelines outline an approach to the assessment of an observable circadian rest-activity rhythm and the diagnosis of circadian rest-activity rhythm disorders (CARDs) in patients with cancer. This study assessed the circadian rest-activity rhythms, prevalence of CARDs and associations with patient characteristics and clinical outcomes in a cohort of patients with advanced cancer. WHAT THIS STUDY ADDS CARDs are common, affecting up to 60% of patients with advanced cancer. Circadian rest-activity rhythms are commonly disordered due to daytime sedentariness and night-time restlessness, but also include variation in rest and physical activity rhythms between days. Potential risk factors for a CARD include more advanced disease, particularly metastatic organ involvement, poorer performance status, higher inflammatory status, anaemia and iron deficiency. Improved circadian rest-activity rhythms were seen in those who share a bed. A diagnosis of a CARD, in patients with advanced cancer, is associated with increased symptom burden, particularly fatigue and drowsiness, and symptom-related distress. Those with a CARD diagnosis also had poorer Global Health Status and functioning subscales. CARDs are common, affecting up to 60% of patients with advanced cancer. Circadian rest-activity rhythms are commonly disordered due to daytime sedentariness and night-time restlessness, but also include variation in rest and physical activity rhythms between days. Potential risk factors for a CARD include more advanced disease, particularly metastatic organ involvement, poorer performance status, higher inflammatory status, anaemia and iron deficiency. Improved circadian rest-activity rhythms were seen in those who share a bed. A diagnosis of a CARD, in patients with advanced cancer, is associated with increased symptom burden, particularly fatigue and drowsiness, and symptom-related distress. Those with a CARD diagnosis also had poorer Global Health Status and functioning subscales. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY The findings of this study warrant further investigation of CARDs in patients with cancer. Research needs to address similarities and differences between different cancer types and further elucidate other risk factors for the development of the diagnosis. More work is also required to examine the implications of the diagnosis on additional clinical outcomes, including the risk of clinical deterioration, hospital admissions and overall prognosis. The findings of this study warrant further investigation of CARDs in patients with cancer. Research needs to address similarities and differences between different cancer types and further elucidate other risk factors for the development of the diagnosis. More work is also required to examine the implications of the diagnosis on additional clinical outcomes, including the risk of clinical deterioration, hospital admissions and overall prognosis. Introduction Circadian rhythms describe physiological and biochemical changes that occur across 24-hour periods.1 Such changes may be demonstrated in observable behaviours, such as sleeping, eating and physical activity, but also in measurable serological changes, such as levels of cortisol and melatonin. Cells throughout the human body function in a circadian fashion under the instruction of several ‘clock’ genes, predominantly period (per), cryptochrome (cry), circadian locomotor output cycles kaput (CLOCK) and Brain and Muscle ARNT-Like 1 (BMAL1) genes.1 However, for physiological processes to be effective, tissues and organs need to function synchronously, and the peripheral clock machinery is coordinated by a central pacemaker, the suprachiasmatic nuclei (SCN), within the hypothalamus.1 The SCN can also interpret environmental factors, predominantly the presence or absence of light, in coordinating internal processes with our environment.1 Circadian disruption is common among patients with cancer and appears to be more pronounced with advancing disease.2 There are several postulated mechanisms leading to circadian disruption within cancer diagnoses, and the association with circadian disruption appears bidirectional. Thus, the presence of cancer, along with anticancer therapies, disrupts physiological and sleep circadian rhythms. Furthermore, circadian disruption may promote cancer development and, in those with a cancer diagnosis, be related to more rapid disease progression.3 Circadian disruption has been linked to important clinical outcomes for patients with cancer, including symptom burden, quality of life measures and survival.2 A circadian rhythm of interest is the circadian rest-activity rhythm. This describes patterns of rest (physical inactivity) and physical activity across the 24-hour period and also between 24-hour periods.4 Patients with disruption of this circadian rest-activity rhythm may demonstrate daytime sedentariness and night-time restlessness, a significant variation in rest-activity patterns between days or a combination of the two. Potentially reversible modifiers of the circadian rest-activity rhythm should be considered in this patient group and may include poorly managed symptoms, sleep-related disorders, blood and electrolyte abnormalities and certain medications.4 Previous studies demonstrate a lack of consistency in methodology (and reporting) of circadian rest-activity rhythms. Recently, however, an international group of experts developed guidelines for the standardised assessment and diagnosis of Circadian rest-Activity Rhythm Disorders (CARDs) in patients with cancer.4 This includes the use of a clinical review, patient diary completion and accelerometry monitoring. Accelerometry devices are worn on the body and measure levels of activity across specified time periods (epochs), with 60s epochs being commonly used.5 Accelerometry allows for a non-invasive and continuous measure of physical activity levels and has been found to be a valid and acceptable approach for patients with cancer (see methodology).6 This is the first study to assess circadian rest-activity rhythms in accordance with new assessment and diagnostic guidelines. The study objectives were: Describe circadian rest-activity rhythms in patients with advanced cancer. Describe circadian rest-activity rhythms in patients with advanced cancer. Identify the prevalence of CARDs in patients with advanced cancer according to the newly formed diagnostic criteria. Identify the prevalence of CARDs in patients with advanced cancer according to the newly formed diagnostic criteria. Identify important associations with CARDs.Patient characteristics.Symptom and quality of life measures. Identify important associations with CARDs. Patient characteristics. Patient characteristics. Symptom and quality of life measures. Symptom and quality of life measures. Methods This prospective, observational study was conducted at a teaching hospital and hospice service in Dublin. The study recruited outpatients with locally advanced or metastatic cancer and was conducted over a 1-year period. Ethical approval was granted by the joint St James’ Hospital–Tallaght University Hospital Research Ethics Committee (ID 1926). The study was registered on ClinicalTrials.gov (NCT06023654). The inclusion criteria were: (i) outpatient; (ii) ≥18 years old; (iii) diagnosis of advanced cancer (locally advanced, incurable, metastatic); (iv) ambulatory and (v) estimated prognosis ≥3 months. The exclusion criteria were: (i) inpatient; (ii) engaged in shift work; (iii) long haul travel in the last 14 days and (iv) cognitive impairment limiting the ability to complete the assessment tool and/or patient diary. All patients who met these criteria were eligible to take part in the study. Potential participants were identified by the clinical team and, with permission, were then approached by the researcher. Patients were provided with a patient information leaflet and given the opportunity to ask the researcher questions. Participants attended at the beginning of a week, provided written consent, and then completed baseline assessments, including demographic and lifestyle information, a clinical history and examination, performance status (Eastern Cooperative Oncology Group score), cognition (Abbreviated Mental Test Score), physical and psychological symptoms (Memorial Symptom Assessment Scale-Short Form (MSAS-SF)), quality of life (European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC-QLQ-C30)) and chronotype (Morningness-Eveningness Questionnaire). At the same time, a wrist accelerometer (Micro Motionlogger® watch, Ambulatory Monitoring, USA) was applied to the non-dominant wrist, and a thigh accelerometer (ActivPal, PAL technologies, UK) was placed in a nitrile sleeve and applied to the middle and anterior aspect of the right thigh before securing with a TegadermTM. Instructions were provided on device care and how to use the event recorder on the Micro Motionlogger® watch to capture the time of getting in and out of bed. Furthermore, participants were provided with a novel Sleep and Activity Diary (online supplemental appendix 1), devised following recently formed recommendations for the assessment of circadian rest-activity rhythms, and instructed on how to use it.4 After a 72-hour period of monitoring, participants returned to complete further assessments relating to sleep quality (brief Pittsburgh Sleep Quality Index (bPSQI)), daytime sleepiness (Epworth Sleepiness Scale), obstructive sleep apnoea (STOP-Bang) and presence of restless legs syndrome. The recently formed recommendations and diagnostic criteria (see table 1) highlight the importance of specific circadian parameters, including the dichotomy index (I5.0, p=0.018) and those with a Eastern Cooperative Oncology Group (ECOG) score of 2 compared with an ECOG score of 0 (p=0.018). Lower dichotomy index values were seen in patients who did not share a bedroom (p=0.009) and who did not drink alcohol (p=0.037). There was also a significant correlation between the dichotomy index and bilirubin level (r=0.251, p=0.045) and albumin (r=0.274, p=0.028). A linear actigram illustrating a ‘good’ dichotomy index (I5, p=0.002) or were smokers (p=0.025). r24 values were correlated with haemoglobin (r=0.34, p=0.007), iron levels (r=0.38, p=0.002), transferrin saturation (r=0.36, p=0.003), sodium (r=0.35, p=0.005), alanine transaminase (ALT) (r=0.271, p=0.03), folate levels (r=0.29, p=0.019), white cell count (WCC) (r=−0.33, p=0.008), CRP (r=−0.36, p=0.004) and alkaline phosphatase (ALP) (r=−0.25, p=0.043). Median SE was 90.35% (range 51.00%–98.36%), with 51 participants (78%) having an SE <86%. SE was significantly worse in those receiving hormonal and chemotherapy treatments compared with combination anticancer therapies (p=0.018 and p=0.043, respectively). Higher SE was associated with higher haemoglobin levels (p=0.04), higher bilirubin levels (p=0.02) and lower ALT levels (p=0.03). A large positive correlation was demonstrated between the I